Convalescent Plasma News and Research

RSS

SARS-CoV-2 cocktail with three antibodies potent in preclinical testing

Amidst growing concerns on the use and potential benefits of convalescent plasma therapy, a research group in the United States has identified three human antibodies (Abs) that, when combined, demonstrate both robust viral suppressive properties against all tested severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Variants of Concern (VoC) in vitro and profound antiviral efficacy in vivo.

22 Oct 2021

Serologic testing algorithm to detect disparities in SARS-CoV-2 infection prevalence and vaccination uptake

A new study recently published on the medRxiv* preprint server demonstrates the use of a serological testing algorithm for identifying disparities in infection rates and vaccine uptake amongst the study population to enable public health interventions.

17 Oct 2021

Ondansetron use associated with increased survival in mechanically ventilated COVID-19 patients

A recent study analyzes real-world data using artificial intelligence to provide insights into using ondansetron, an antiemetic agent, among SARS-CoV-2 positive patients.

14 Oct 2021

Accumulation of SARS-CoV-2 mutations reduces sensitivity to neutralizing antibodies

In a new study, researchers discovered that SARS-CoV-2 mutations accumulate, especially in immunocompromised patients.

10 Oct 2021

Powerful neutralizing antibody against SARS-CoV-2 variants of concern

A new paper discusses a new antibody with potent neutralizing activity against the ancestral SARS-CoV-2 strain, as well as newer variants of SARS-CoV-2.

10 Oct 2021

Adapting biological research and development to COVID-19

In this interview, News-Medical talks to Dr Yuning Chen, about the work he does with Sino Biological and how they have adapted their research & development to the COVID-19 pandemic.

From Sino Biological Inc. 8 Oct 2021

SARS-CoV-2 evolution promoted by long-term infection in patient with B cell depletion

A new study published on the medRxiv* preprint server focused on a patient with a persistent symptomatic viral infection for over a year. Researchers amplified sub-genomic transcripts for the E gene (sgE) using nasopharyngeal samples of the patient infected with SARS-CoV-2 over the course of 335 days.

6 Oct 2021

Enisamium shows potential as antiviral therapy for COVID-19

Researchers studied the effect of enisamium on the growth and proliferation of Caco-2 and normal human bronchial epithelial cells.

6 Oct 2021

Convalescent plasma is "futile" as COVID-19 treatment for critically ill patients, trial shows

In the earliest days of the COVID-19 pandemic, the medical community turned to a century-old treatment: Take blood from recovered patients and give it to the sick.

4 Oct 2021

Prevalence of adaptive and prolonged infections’ mutations in receptor-binding domain of SARS-CoV-2 spike protein

A new study used the available nucleotide sequence data on the NCBI COVID-19 database and estimated the global prevalence of adaptive and prolonged infections' mutations in the RBD of the S protein.

4 Oct 2021

Enveloped virus-like particle based vaccines potentially broaden immunity against SARS-CoV-2 variants

A new preprint describes promising results with a novel vaccine candidate designed to improve the breadth of neutralization.

1 Oct 2021

Comparison of Pfizer, Moderna, J&J, AZ vaccines for neutralization titer, against Delta and other variants

Is one COVID vaccine better than the other? Four current vaccines — Moderna, Pfizer-BioNTech, Johnson & Johnson, and AstraZeneca — are highly effective against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but a new medRxiv* study suggests the level of protection varies.

30 Sep 2021

Chronic COVID-19 and divergent variants of SARS-CoV-2

A new study discusses the isolation of two variants of concern (VOCs) from an immunocompromised COVID-19 patient.

27 Sep 2021

A new SARS-CoV-2 variant (B.1.1.523) capable of escaping immune protections

A new study describes a new variant that possesses a novel combination of various concerning mutations at the spike region.

27 Sep 2021

People with natural immunity and subsequent mRNA vaccination can neutralize viral particles capable of resisting vaccine-induced antibodies

New research suggests SARS-CoV-2 spike protein substitution mutations can create a replication-defective viral particle that makes the virus resistant to vaccine-induced antibodies.

23 Sep 2021

Convalescent Plasma News and Research

SARS-CoV-2 cocktail with three antibodies potent in preclinical testing

Serologic testing algorithm to detect disparities in SARS-CoV-2 infection prevalence and vaccination uptake

Ondansetron use associated with increased survival in mechanically ventilated COVID-19 patients

Accumulation of SARS-CoV-2 mutations reduces sensitivity to neutralizing antibodies

Powerful neutralizing antibody against SARS-CoV-2 variants of concern

Adapting biological research and development to COVID-19

SARS-CoV-2 evolution promoted by long-term infection in patient with B cell depletion

Enisamium shows potential as antiviral therapy for COVID-19

Convalescent plasma is "futile" as COVID-19 treatment for critically ill patients, trial shows

Prevalence of adaptive and prolonged infections’ mutations in receptor-binding domain of SARS-CoV-2 spike protein

Enveloped virus-like particle based vaccines potentially broaden immunity against SARS-CoV-2 variants

Comparison of Pfizer, Moderna, J&J, AZ vaccines for neutralization titer, against Delta and other variants

Chronic COVID-19 and divergent variants of SARS-CoV-2

A new SARS-CoV-2 variant (B.1.1.523) capable of escaping immune protections

People with natural immunity and subsequent mRNA vaccination can neutralize viral particles capable of resisting vaccine-induced antibodies

Decline in SARS-CoV-2 neutralizing antibodies and unique cytokine profile in severe COVID-19 patients

Failures and findings from randomized clinical trials in COVID-19 convalescent plasma

Characterizing the flexibility of SARS-CoV-2 variant of concern spike proteins

Convalescent plasma shows no benefit in hospitalized COVID-19 patients

Study identifies broadly neutralizing antibody panel against SARS-like viruses

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News